Scarica l'app Stockscreener
0.0741
6.62%
0.0046
Dopo l'orario di chiusura:
.07
-0.0041
-5.53%
Onconetix Inc Borsa (ONCO) Ultime notizie
Onconetix Stockholders Approve Reverse Stock Split Proposal - TipRanks
Onconetix, Inc. Reports Earnings Results for the Full Year Ended December 31, 2024 - marketscreener.com
Onconetix, Inc. SEC 10-K Report - TradingView
Onconetix receives additional delisting notice from Nasdaq - Yahoo Finance
Onconetix faces potential Nasdaq delisting over filing delays By Investing.com - Investing.com Nigeria
Onconetix receives additional notice from Nasdaq - MSN
Onconetix Faces Nasdaq Delisting Notice Amid Compliance Issues - TipRanks
Onconetix faces potential Nasdaq delisting over filing delays - Investing.com Australia
Onconetix, Inc. Receives Nasdaq Delisting Letter for Failure to File Quarterly Report and Maintain Minimum Bid Price Requirements - Nasdaq
Onconetix, Inc. Announces Receipt of Additional Notice from Nasdaq - GlobeNewswire
Onconetix Faces Triple Threat: Nasdaq Delisting Risk Over Missing Filings and 10-Cent Stock Price - Stock Titan
Noram Receives Results for CVZ-66: High of 1540 ppm Intersection of 220ft (67.1 m) Averaging 1124 ppm of Lithium - The Globe and Mail
ONCOOnconetix Latest Stock News & Market Updates - Stock Titan
Correction: Onconetix Announces Financing Through a $2.0 Million Private Placement of Series C Preferred Stock and Warrants, Establishes a $25 Million Equity Line of Credit - Barchart.com
Critical Alert: Onconetix Hit With Second Nasdaq Delisting Notice as Deadline Looms - Stock Titan
Onconetix Inc [ONCO] Is Currently 14.45 above its 200 Period Moving Avg: What Does This Mean? - dbtnews.com
Onconetix Inc (ONCO) expanding its growth trajectory ahead - Sete News
ONCO Stock on the Rise: A Promising Investment - investchronicle.com
This morning’s top pick is Onconetix Inc (NASDAQ:ONCO) - uspostnews.com
Take off with Onconetix Inc (ONCO): Get ready for trading - Sete News
ONCO’s Stock Market Pendulum: Swinging Between Gains and Losses - investchronicle.com
Form 424B3Prospectus [Rule 424(b)(3)] - ADVFN
Form 8-KCurrent report - ADVFN
Onconetix faces third delisting threat since 2022 IPOCincinnati Business Courier - The Business Journals
Onconetix faces Nasdaq delisting over low share price By Investing.com - Investing.com India
Onconetix faces Nasdaq delisting over low share price - Investing.com
ONCO’s current quarter earnings: What analysts forecast? - uspostnews.com
ONCO stock plunges to 52-week low, touches $0.06 - Investing.com Australia
ONCO stock plunges to 52-week low, touches $0.06 By Investing.com - Investing.com South Africa
Cincinnati's Onconetix pursuing merger deal with drug development firm - The Business Journals
Onconetix Sets Stage For Potential Business Combination With Ocuvex Therapeutics - marketscreener.com
Onconetix, Ocuvex Therapeutics Sign Letter of Intent for Potential Merger; Shares Up Pre-Bell - marketscreener.com
Onconetix eyes Ocuvex in potential merger to expand portfolio By Investing.com - Investing.com India
Onconetix Inks Letter Of Intent For Potential Business Combination With Ocuvex - Nasdaq
Onconetix Signs Letter of Intent for Potential Business Combination with Ocuvex Therapeutics, Inc. - The Manila Times
Max Alderman, Partner at FE International, Recognized as a NACVA 2024 30 Under Thirty Honoree - The Manila Times
Onconetix eyes Ocuvex in potential merger to expand portfolio - Investing.com
Target Corp (TGT) Stock: 52-Week Performance Showcases Highs, Lows, and Trading Volume - investchronicle.com
Major Pipeline Expansion: Onconetix to Acquire FDA-Approved Eye Drug in Ocuvex Deal - Stock Titan
Another top executive departs Cincinnati public firm - WKRC
Onconetix executive chairman resigns in latest leadership exit; interim CFO named new top leader - The Business Journals
Onconetix Names Interim CFO Karina Fedasz as Interim CEO - MarketWatch
Onconetix Appoints Karina Fedasz as Interim CEO - TipRanks
Onconetix Delays Yearly Report Filing - TipRanks
Pre-market Movers: RGLS, SLNO, OCEA, OSRH... - RTTNews
Onconetix claims validation of prostate cancer test Proclarix in Danish cohort - Yahoo Finance
Onconetix Announces Successful Clinical Validation of its Innovative Prostate Cancer Test Proclarix in a Danish cohort - GlobeNewswire
Onconetix reveals Proclarix’s clinical performance at EAU congress - Investing.com India
Onconetix Announces Successful Clinical Validation Of Proclarix For Prostate Cancer In Danish Cohort - Nasdaq
Onconetix reveals Proclarix’s clinical performance at EAU congress By Investing.com - Investing.com South Africa
Onconetix Inc. Presents Promising Clinical Data for Proclarix® at 2025 EAU Congress - Nasdaq
1.21%
1.51%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):